Bin Li

Dr. Bin Li

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
XSXin Song
Xin Song
GZGuiming Zhang
Guiming Zhang
XMXiao-Cheng Ma
Xiao-Cheng Ma
LLLei Luo
Lei Luo
BLBin Li
Bin Li
LSLi-Jiang Sun
Li-Jiang Sun
Purpose: The aim of this study was to investigate the prognostic value of preoperative neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), and lymphocyte–monocyte ratio (LMR) in patients with upper urinary tract urothelial carcinoma (UUTUC). Methods: We retrospectively analyzed the clinical data of 140 patients with UUTUC who underwent radical nephroureterectomy from January 2005 to December 2011. We plotted receiver operating characteristic curves of NLR, PLR, and LMR for the diagnosis of tumor recurrence. Survival analysis was performed using the Kaplan–Meier method and log-rank test. Independent risk factor analysis was performed using a Cox proportional hazards regression model. Results: Receiver operating characteristic curves showed that NLR was superior to PLR and LMR as a predictive factor in patients with UUTUC undergoing radical nephroureterectomy. Univariate analysis revealed that NLR (P<0.001 and P<0.001), PLR (P=0.01 and P<0.001), and LMR (P<0.001 and P<0.001) were significantly associated with disease-free survival and progression-free survival (PFS), respectively. Multivariate analysis identified NLR and LMR as independent prognostic factors for disease-free survival (P=0.035 and P=0.002) and PFS (P=0.005 and P=0.002), respectively. Conclusion: NLR and LMR could be independent predictors of disease-free survival and PFS, and NLR is a superior predictive factor to LMR.

7 February 2022 in BMC Medicine
Verified
Journal Article
Open access
PDF file
ZQZhiquan Qiu
Zhiquan Qiu
JJJun Ji
Jun Ji
YXYu Xu
Yu Xu
YZYan Zhu
Yan Zhu
CGChunfang Gao
Chunfang Gao
XJXiao-Qing Jiang
Xiao-Qing Jiang
Background: DNA methylation-associated studies on biliary tract cancer (BTC), including cholangiocarcinoma (CCA) and gallbladder cancer (GBC), may improve the BTC classification scheme. We proposed to identify the shared methylation changes of BTCs and investigate their associations with genomic aberrations, immune characteristics, and survival outcomes. Methods: Multi-dimensional data concerning mutation, DNA methylation, immune-related features, and clinical data of 57 CCAs and 48 GBCs from Eastern Hepatobiliary Surgery Hospital (EHSH) and 36 CCAs in the TCGA-CHOL cohort were analyzed. Results: In our cohort including 24 intrahepatic CCAs (iCCAs), 20 perihilar CCAs (pCCAs), 13 distal CCAs (dCCAs), and 48 GBCs, 3369 common differentially methylated regions (DMRs) were identified by comparing tumor and non-tumor samples. A lower level of methylation changes of these common DMRs was associated with fewer copy number variations, fewer mutational burden, and remarkably longer overall survival (OS, hazard ratio [HR] = 0.07, 95% confidence interval [CI] 0.01–0.65, P = 0.017). Additionally, a 12-marker model was developed and validated for prognostication after curative surgery (HR = 0.21, 95% CI 0.10–0.43, P < 0.001), which exhibited undifferentiated prognostic effects in subgroups defined by anatomic location (iCCAs, d/pCCAs, GBCs), TNM stage, and tumor purity. Its prognostic utility remained significant in multivariable analysis (HR = 0.26, 95% CI 0.11–0.59, P = 0.001). Moreover, the BTCs with minimal methylation changes exhibited higher immune-related signatures, infiltration of CD8+ lymphocytes, and programmed death-ligand 1 (PD-L1) expression, indicating an inflamed tumor immune microenvironment (TIME) with PD-L1 expression elicited by immune attack, potentially suggesting better immunotherapy efficacy. Conclusions: In BTCs, DNA methylation is a powerful tool for molecular classification, serving as a robust indicator of genomic aberrations, survival outcomes, and tumor immune microenvironment. Our integrative analysis provides insights into the prognostication after curative surgery and patient selection for immunotherapy.

30 August 2024 in International Immunopharmacology
Verified
Journal Article
Open access
PZPei-Lin Zhao
Pei-Lin Zhao
XGXing Gao
Xing Gao
XLXuan Li
Xuan Li
YMYu-Qi Meng
Yu-Qi Meng
ZLZhen-Qing Li
Zhen-Qing Li
BLBin Li
Bin Li
Limited research has focused on the role of dihydrouridine synthases (DUS) family members in human tumors. Our previous findings indicated an impact of dihydrouridine synthase 4 like (DUS4L) on cell proliferation and apoptosis in lung adenocarcinoma (LUAD) A549 cell, yet its broader functions and regulatory mechanisms in LUAD remain elusive. Using a LUAD tissue microarray and immunohistochemical (IHC) staining, we validated variations in DUS4L protein expression levels among LUAD patients and assessed its clinical significance. Additional experiments using short hairpin RNA (shRNA) against DUS4L (sh-DUS4L-2), LUAD cell lines, cell function assays (including wound healing, transwell migration and invasion, colony formation, and apoptosis assays), and mouse tumor xenografts were performed to examine the biological roles of DUS4L in LUAD progression. RNA sequencing, proteomic analyses, mass spectrometry, and co-immunoprecipitation experiments were conducted to identify and validate DUS4L-regulated downstream target genes and signaling pathways. We identified a consistent upregulation of DUS4L in LUAD tissues. In vitro and in vivo experiments underscored the inhibitory effect of DUS4L downregulation on LUAD progression, including migration, invasion, and proliferation. Mechanistically, DUS4L was found to interact with the signaling molecule GRB2, promoting LUAD progression and metastasis by inducing epithelial-mesenchymal transition (EMT) via the PI3K/AKT and ERK/MAPK pathways. Our results establish the functional role of DUS4L in driving the progression and metastasis of LUAD, implicating its potential as a candidate therapeutic target for LUAD.

1 November 2011 in Orthopedics
Verified
Journal Article
Closed access
LZLi-juan Zhu
Li-juan Zhu
BLBin Li
Bin Li
LTLi-Jie Tian
Li-Jie Tian
Little research has been done regarding the treatment of severe hand deformities caused by epidermolysis bullosa. A 14-year-old boy was diagnosed with congenital epidermolysis bullosa. He was treated in our hospital several times, but the pathogenetic condition worsened. On examination, both hands were clenched fists and had scar formation. Skin fusion was observed between the 5 fingers. Nails were absent and the thumb was in the fist. His fingers were short, and active and passive flexion and extension could not be performed. The right hand was treated first. After the adhesions were separated, we found that the 5 fingers were connected by dermis. After the dermis was separated and the hand was fixed in the extension position, there were small cutaneous deficiencies. The fingers were fixed in the functional position with Kirschner wires. The wound surface was covered with self-made aureomycin ointment gauze. After regular dressing changes for 6 weeks, the wound surface was completely healed. After 3 months of rehabilitation training, most hand function was recovered. Based on our findings in this case, when treating patients with epidermolysis bullosa, physicians must carefully observe whether enough dermis exists to avoid an unnecessary skin graft. We also found that the quality of skin used in skingrafting is questionable due to pathological changes in the skin. If there is enough dermis and the cutaneous deficiency is smaller after contracture release, the covering of drug dressings on the cutaneous deficiency is more conducive to the recovery of limb function and the reduction of damage to the donor sites.

9 July 2026 in New England Journal of Medicine
Verified
Journal Article
Closed access
DYDongsheng Yue
Dongsheng Yue
MHMeijuan Huang
Meijuan Huang
PSPingping Song
Pingping Song
YCYuejun Chen
Yuejun Chen
BLBin Li
Bin Li
EGELEVATE Study Group
ELEVATE Study Group
Anaplastic lymphoma kinase (ALK) inhibitors have emerged as promising agents for patients with resectable ALK-positive non-small-cell lung cancer (NSCLC). Whether ensartinib, a second-generation ALK inhibitor, is safe and effective in such patients is unknown. In this phase 3, double-blind, randomized trial involving patients with completely resected, ALK-positive stage IB to IIIB NSCLC after adjuvant chemotherapy, we randomly assigned patients in a 1:1 ratio to receive ensartinib at a dose of 225 mg once daily or placebo for 24 months. The primary end point was disease-free survival in patients with stage II to IIIB NSCLC. The key secondary end point was disease-free survival in the overall patient population. A total of 274 patients were randomly assigned to receive ensartinib or placebo (137 patients in each group). At 24 months, the percentage of patients with stage II to IIIB disease who were alive and disease-free was 86.4% in the ensartinib group and 53.5% in the placebo group (hazard ratio for disease recurrence or death, 0.20; 95% confidence interval [CI], 0.11 to 0.38; P<0.001). In the overall patient population, the percentage of patients who were alive and disease-free was 87.3% in the ensartinib group and 57.2% in the placebo group (hazard ratio, 0.20; 95% CI, 0.10 to 0.37; P<0.001). Overall survival data were immature. Adverse events of grade 3 or higher occurred in 35.8% of the patients who received ensartinib (most commonly rash) and in 18.2% of those who received placebo. Among patients with completely resected stage IB to IIIB ALK-positive NSCLC, the percentage of patients who were alive and disease-free at 24 months was significantly higher with ensartinib than with placebo. (Funded by Betta Pharmaceuticals; ELEVATE ClinicalTrials.gov number, NCT05341583.).

3 March 2022 in Chinese Medical Journal
Verified
Journal Article
Open access
HLHan Lv
Han Lv
MLMengyi Li
Mengyi Li
ZWZhenchang Wang
Zhenchang Wang
DYDa-wei Yang
Da-wei Yang
HXHui Xu
Hui Xu
ZZZhongtao Zhang
Zhongtao Zhang
An abstract is unavailable. This article is available as a PDF only.